Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.09 USD
Change Today +0.18 / 1.65%
Volume 1.8M
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

455 Mission Bay Boulevard South

San Francisco, CA 94158

United States

Phone: 415-482-5300

Fax: 415-339-5300

Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The company’s proprietary pipeline comprises drug candidates across various therapeutic areas, including oncology, pain, anti-infectives and immunology. The company’s research and development activities involve small molecule drugs, peptides and other biologic drug candidates. The company creates drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of pharmacophores to create new molecular entities. The company’s most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, for the treatment of opioid-induced constipation (OIC), in patients with non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain medicines. Naloxegol has been specifically designed as a once-daily tablet to block the binding of opioids to the opioid receptors in the gastrointestinal tract while not crossing the blood brain barrier and impacting the analgesic activity of opioids binding to opioid receptors in the brain. In 2013, the company’s collaboration partner AstraZeneca PLC (AstraZeneca) announced that the United States Food and Drug Administration (FDA), accepted the New Drug Application (NDA), for naloxegol, with a Prescription Drug User Fee Act (PDUFA), date of September 16, 2014. AstraZeneca also has filed marketing applications for naloxegol with health authorities in the European Union (E.U.) and Canada. The company’s second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, being evaluated in a Phase 3 clinical study as a single-agent therapy for women with metastatic breast cancer. This Phase 3 clinical study, which is called as the BEACON study (BrEAst Cancer Outcomes with NKTR-102), was initiated by the company in December 2011 and enrollment completed in July 2013. The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate. In 2012, the FDA designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine. The company also has studied or provided support for ongoing studies being conducted for etirinotecan pegol in bevacizumab (Avastin)-resistant high-grade glioma, colorectal cancer, metastatic and recurrent non-small cell lung cancer, and ovarian cancer. The company’s third most advanced proprietary drug candidate, NKTR-181, is a novel mu-opioid analgesic drug candidate for chronic pain conditions. In 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. In 2013, the company conducted a human abuse liability study, or HAL study, for NKTR-181. The company also has additional proprietary preclinical and clinical drug candidates being developed for pain relief. In January 2014, the company announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain. NKTR-171 is a new molecular entity that is specifically designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system. NKTR-171 is designed to be a peripherally-restricted molecule, with the aim of not causing central nervous system (CNS) side effects that limit usage of existing therapies. In addition, the company is also developing NKTR-192, a novel mu-opioid analgesic molecule with a short-acting profile designed to treat acute pain while addressing the serious CNS-related side

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.09 USD +0.18

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $22.67 USD +0.80
Emergent Biosolutions Inc $28.52 USD +0.67
Ironwood Pharmaceuticals Inc $15.67 USD +0.23
Sucampo Pharmaceuticals Inc $14.50 USD +0.50
Theravance Inc $16.46 USD -0.13
View Industry Companies
 

Industry Analysis

NKTR

Industry Average

Valuation NKTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.1x
Price/Book 40.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit www.nektar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.